In the setting of viral suppression, there are many reasons to optimize antiretroviral therapy (ART); however, there are also factors to consider before switching or simplifying therapy, including the patient’s full treatment history and preference. After switching, it is imperative to monitor for potential side effects that could result in discontinuation, especially as long-term ART exposure contributes to the burden of renal disease.
In this CME Outfitters Briefcase, faculty will highlight a patient case that focuses on seizing opportunities to optimize and simplify treatment for patients with human immunodeficiency virus (HIV) while maintaining virologic suppression, as well as best practices for engaging patients in shared decision-making so that patient preference is always considered.
At the end of this CME/CE activity, participants should be able to determine appropriate strategies for treatment switching.
The following learning objectives pertain only to those requesting CNE or CPE credit: Describe appropriate strategies for treatment switching.
Supported by independent educational grants from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. The supporters were not involved in the development of content or the selection of faculty for this educational activity.
Infectious disease specialists, primary care physicians, PAs, nurse practitioners, nurses, pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Mena reports that he receives grants from Binx Health, Inc.; Click Diagnostics; Evofem Biosciences, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline/ViiV Healthcare; Janssen Pharmaceuticals, Inc.; Merck & Co.; Prosoft Clinical; Roche Molecular Diagnostics; and SpeeDx Pty. Ltd. He is on the advisory committee for Gilead Sciences, Inc.; Merck & Co.; Roche Molecular Diagnostics; and ViiV Healthcare.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.